Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Feasibility Study to Evaluate Performance of the LUM Imaging System for Intraoperative Detection of Residual Tumor in Breast Cancer Patients Receiving and Not Receiving Neoadjuvant Therapy

Next Previous
Search
Trial Profile

Feasibility Study to Evaluate Performance of the LUM Imaging System for Intraoperative Detection of Residual Tumor in Breast Cancer Patients Receiving and Not Receiving Neoadjuvant Therapy

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegulicianine acetate (Primary)
  • Indications Ductal carcinoma; Early breast cancer
  • Focus Adverse reactions; Diagnostic use
  • Sponsors Lumicell

    • Most Recent Events

    • 11 Mar 2024 Status changed from recruiting to discontinued.
    • 19 Apr 2023 According to Trial design presented at the 114th Annual Meeting of the American Association for Cancer Research, Cohort 1 has completed enrollment and interim analysis.
    • 19 Apr 2023 Trial Design presented at the 114th Annual Meeting of the American Association for Cancer Research

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top